Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805293/0/en/Mereo-BioPharma-Provides-Update-on-Pipeline-Progress-and-Corporate-Developments.html

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024

Read more at globenewswire.com

Related news for (MREO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.